Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Relevance of Carotid Reocclusion in Tandem Lesions

  • Zapata‐Arriaza, Elena
  • Medina-Rodríguez, Manuel
  • Ortega-Quintanilla, Joaquín
  • Albóniga-Chindurza, Asier de
  • Ainz-Gómez, Leire
  • Pardo‐Galiana, Blanca
  • Cabezas, Juan A.
  • Lebrato, Lucía
  • Barragán-Prieto, Ana
  • Pérez-Sánchez, Soledad
  • Zamora, Aynara
  • Montaner, Joan
  • González-García, Alejandro
  • Moniche, Francisco
© 2023 Japan Atherosclerosis Society. This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License., Aims: Carotid reocclusion (CRO) after mechanical thrombectomy (MT) in acute ischemic stroke (AIS) due to tandem lesion (TL) or isolated internal carotid occlusion (ICO) is associated with worse clinical outcomes. Our aim was to analyze the predictors and clinical impact of CRO. Methods: A retrospective single-center analysis of all patients with anterior circulation strokes who underwent MT prospectively included in a registry between 2017 and 2020 was performed. ICO and TL as stroke causes were included. Stent deployment was left to the discretion of the interventionist. All patients received at least intravenous aspirin during MT. CRO was assessed using ultrasound within the first 24 h after MT. Efficacy and safety of stenting were assessed. Results: Among 1304 AIS cases, 218 (16.7%) were related to TL or ICO. Of them, 5% (n=11) were associated with internal CRO 24 h after the endovascular procedure. After adjusting per confounders, multivariate analysis showed that the independent variables associated with CRO were the TICI recanalization grade [TICI 2b–3; OR 0.1, 95% confidence interval (CI) 0.01–0.89, p=0.040], pial collateral circulation presence (OR 0.09, 95% CI 0.02–0.45, p=0.03), stent deployment during MT (OR 0.17, 95% CI 0.03–0.84, p=0.030), and general anesthesia use (OR 2.92, 95% CI 1.13–7.90, p=0.034). CRO showed a trend toward worst outcomes (modified Rankin scale 3–6) at 3 months (OR 3.4, 95% CI 0.96–12, p=0.057). After multivariate analysis, variables independently associated with worse outcomes at 90 days were intrastent platelet aggregation phenomena during endovascular therapy, admission National Institute of Health Stroke Scale, and age. Conversely, intravenous thrombolysis and TICI 2b–3 recanalization grade were identified as independent predictors of good outcomes at 90 days. Conclusions: CRO has a relevant clinical impact in our study, associating lower rates of good functional outcomes at 3 months. Independent factors of CRO were the recanalization degree, presence of pial collateral circulation, use of a stent as a protective factor, and use of general anesthesia during thrombectomy., This project was funded by the Instituto de Salud Carlos III (ISCIII) through the project PI21/01322 and co-funded by the European Union. The ITRIBiS project (Improving Translational Research Potential at the Institute of Biomedicine of Seville) has the registration number REGPOT-2013-1. M. Medina was granted a Rio Hortega contract. The project was included in the Cooperative Cerebrovascular Disease Research Network (INVICTUS) (RD16/0019/0015)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol

  • Medina-Rodríguez, Manuel
  • Moniche, Francisco
  • Albóniga-Chindurza, Asier de
  • Ortega-Quintanilla, Joaquín
  • Ainz-Gómez, Leire
  • Pardo‐Galiana, Blanca
  • Cabezas, Juan A.
  • Aguilar-Pérez, Marta
  • Zamora, Aynara
  • Delgado-Acosta, Fernando
  • Jiménez-Gómez, Elvira
  • Bravo-Rey, Isabel
  • Oteros-Fernández, Rafael
  • Freijo-Guerrero, Maria del Mar
  • González-Díaz, Eva
  • Escudero-Martínez, Irene
  • Morales-Caba, Lluis
  • Vielba-Gómez, Isabel
  • Mosteiro, Sonia
  • Castellanos-Rodrigo, María del Mar
  • Pascasio, Laura Amaya
  • Hidalgo, Carlos
  • Fernández-Prudencio, Luis
  • Ramírez-Moreno, José M.
  • Díaz-Pérez, José
  • Sanz-Fernández, Gema
  • Baena-Palomino, Pablo
  • Gamero-García, Miguel Ángel
  • Jiménez-Jorge, Silvia
  • Rosso-Fernández, Clara
  • Montaner, Joan
  • González-García, Alejandro
  • Zapata‐Arriaza, Elena
[Background] In-stent thrombosis after mechanical thrombectomy (MT) worsen outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Although an optimal antiplatelet therapy is needed, the best approach to avoid in-stent thrombosis is yet to be elucidated., [Hypothesis] Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL., [Methods] The ATILA-trial is a multicenter, prospective, phase IV, randomized, controlled (aspirin group as control), assessor-blinded clinical trial. Patients fulfilling inclusion criteria (AIS due to TL, ASPECTS ⩾ 6, pre-stroke modified Rankin Scale ⩽2 and onset <24 h) will be randomized (1:1) at MT onset to experimental (intravenous tirofiban) or control group (intravenous aspirin). Intravenous aspirin will be administered at a 500 mg single dose and tirofiban at a 500 µg bolus followed by a 200 µg/h infusion during first 22 h. All patients will be followed up to 3 months. Sample size estimated is 240 patients., [Outcomes] The primary efficacy outcome is the proportion of patients with carotid in-stent thrombosis within the first 24 h after MT. The primary safety outcome is the rate of symptomatic intracranial hemorrhage. Secondary outcomes include functional independence defined as modified Rankin Scale 0–2, proportion of patients undergoing rescue therapy due to in-stent aggregation during MT and carotid reocclusion at 30 days., [Discussion] ATILA-trial will be the first clinical trial regarding the best antiplatelet therapy to avoid in-stent thrombosis after MT in patients with TL., [Trial registration] NCT0522596., This project was funded by the Instituto de Salud Carlos III (ISCIII) through the project PI21/01322 and co-funded by the European Union. The Spanish Clinical Research Network (SCReN-Code:21.033) also contributed to the study. The ITRIBiS project (Improving Translational Research Potential at the Institute of Biomedicine of Seville) has the registration number REGPOT-2013-1. M. Medina-Rodríguez was granted a Rio Hortega contract (CM21/00096). The project was included in the Cooperative Cerebrovascular Disease Research Network (INVICTUS) (RD16/0019/0015)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial)

  • Zapata‐Arriaza, Elena
  • Medina-Rodríguez, Manuel
  • Moniche, Francisco
  • Albóniga-Chindurza, Asier de
  • Aguilar-Pérez, Marta
  • Ainz-Gómez, Leire
  • Baena-Palomino, Pablo
  • Zamora, Aynara
  • Pardo‐Galiana, Blanca
  • Delgado, Fernando
  • Valverde Moyano, Roberto
  • Jiménez-Gómez, Elvira
  • Bravo-Rey, Isabel
  • Oteros-Fernández, Rafael
  • Escudero-Martínez, Irene
  • Vielba-Gómez, Isabel
  • Morales-Caba, Lluis
  • Díaz-Pérez, José
  • García-Molina, Estefanía
  • Mosteiro, Sonia
  • Castellanos-Rodrigo, María del Mar
  • Pascasio, Laura Amaya
  • Hidalgo, Carlos
  • Freijo-Guerrero, Maria del Mar
  • González-Díaz, Eva
  • Ramírez-Moreno, José M.
  • Fernández-Prudencio, Luis
  • Terceño Izaga, Mikel
  • Bashir Viturro, Saima
  • Gamero-García, Miguel Ángel
  • Jiménez-Jorge, Silvia
  • Rosso-Fernández, Clara
  • Montaner, Joan
  • González, Alejandro
© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data., [Rationale] In-stent reocclusion after endovascular therapy has a negative impact on outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Optimal antiplatelet therapy approach in these patients to avoid in-stent reocclusion is yet to be elucidated., [Aims] To assess efficacy and safety of intravenous tirofiban versus intravenous aspirin in patients undergoing MT plus carotid stenting in the setting of AIS due to TL., [Sample size estimates] Two hundred forty patients will be enrolled, 120 in every treatment arm., [Methods and design] A multicenter, prospective, randomized, controlled (aspirin group), assessor-blinded clinical trial will be conducted. Patients fulfilling the inclusion criteria will be randomized at MT onset to the experimental or control group (1:1). Intravenous aspirin will be administered at a 500-mg single dose and tirofiban at a 500-mcg bolus followed by a 200-mcg/h infusion during the first 24 h. All patients will be followed for up to 3 months., [Study outcomes] Primary efficacy outcome will be the proportion of patients with carotid in-stent thrombosis within the first 24 h after MT. Primary safety outcome will be the rate of symptomatic intracranial hemorrhage., [Discussion] This will be the first clinical trial to assess the best antiplatelet therapy to avoid in-stent thrombosis after MT in patients with TL., [Trial registration] The trial is registered as NCT05225961. February, 7th, 2022., This project was funded by the Instituto de Salud Carlos III (ISCIII) through the project PI21/01322 and co-funded by the European Union. The Spanish Clinical Research Network (SCReNCode: 21.033) also contributed to the study. The ITRIBiS project (Improving Translational Research Potential at the Institute of Biomedicine of Seville) has the registration number REGPOT-2013-1. M. Medina-Rodríguez was granted a Rio Hortega contract (CM21/00096). The project was included in the Cooperative Cerebrovascular Disease Research Network (INVICTUS) (RD16/0019/0015)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tirofiban versus aspirin to prevent in-stent thrombosis after emergent carotid artery stenting in acute ischemic stroke

  • Medina-Rodríguez, Manuel
  • Villagran, Diego
  • Luque-Ambrosiani, Antonio
  • Cabezas Rodríguez, Juan Antonio
  • Ainz-Gómez, Leire
  • Baena Palomino, Pablo
  • Pardo‐Galiana, Blanca
  • Zamora, Aynara
  • Albóniga-Chindurza, Asier de
  • Aguilar-Pérez, Marta
  • González, Alejandro
  • Moniche, Francisco
  • Zapata‐Arriaza, Elena
[Background] Several antithrombotic treatments during emergent carotid artery stenting (eCAS) have been proposed, but an appropriate protocol to balance risk–benefit is not well known., [Objective] To investigate the efficacy and safety of tirofiban compared with aspirin in patients with acute ischemic stroke undergoing eCAS., [Methods] We conducted a retrospective single-center study of the prospective ARTISTA Registry, including patients with atherosclerotic internal carotid artery occlusion treated with eCAS. Two groups, according to antiplatelet drug, were studied: aspirin (250–500 mg single-dose) versus tirofiban (500 μg bolus+200 μg/h). Primary outcomes were the rate of in-stent thrombosis and symptomatic intracranial hemorrhage (sICH) within the first 24 hours., [Results] During the period 2019–2023, 181 patients were included, 103 received aspirin, 78 tirofiban; 149 (82.3%) had tandem lesions. The primary efficacy outcome occurred in 9 (9.4%) in the aspirin group, as compared with 1 (1.3%) in the tirofiban group (adjusted odds ratio (aOR)=0.11, 95% CI 0.01 to 0.98; P=0.048). The primary safety outcome was detected in 12 (11.7%) in the aspirin group, as compared with 2 (2.6%) in the tirofiban group (aOR=0.16, 95% CI 0.03 to 0.87; P=0.034). The tirofiban group presented a lower risk of parenchymal hemorrhage (18 (17.4%) vs 4 (5.2%), aOR=0.27, 95% CI 0.09 to 0.88; P=0.029) and an increased rate of excellent recanalization (expanded Treatment in Cerebral Infarction (eTICI) 2c–3) (50 (48.5%) vs 54 (69.2%); aOR=2.15, 95% CI 1.12 to 4.13; P=0.02). There were no differences in functional outcomes or mortality at 3 months., [Conclusions] Periprocedural antithrombotic therapy with tirofiban was associated with a lower risk of in-stent thrombosis and sICH at 24 hours from eCAS compared with aspirin. Prospective randomized clinical trials are needed to confirm our results., This project was funded by the Instituto de Salud Carlos III (ISCIII) through the project PI21/01322 and co-funded by the European Union. The Spanish Clinical Research Network (SCReN-Code:21.033) also contributed to the study. The ITRIBiS project (Improving Translational Research Potential at the Institute of Biomedicine of Seville) has the registration number REGPOT-2013-1. MM-R was granted a Rio Hortega contract (CM21/00096). The project was included in the Spanish research network “Redes de Investigación Cooperativa Orientadas a Resultados en Salud” (RICORS-ICTUS) (RD21/0006/0015)., Peer reviewed